# Tumefactive multiple sclerosis
**Tumefactive multiple sclerosis** (TMS), also called tumefactive demyelinating lesion (TDL), is a rare variant of multiple sclerosis in which demyelinating lesions in the central nervous system grow larger than 2 cm and mimic brain tumors on magnetic resonance imaging (MRI), typically with little or no mass effect relative to lesion size, perilesional edema, and ring-shaped contrast enhancement.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) • [2](https://link.springer.com/article/10.1186/s12883-025-04495-9) The name refers to the tumor-like appearance of the lesions, not to any neoplastic process; the lesions are inflammatory areas of myelin loss.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/)
| Key fact | Detail |
|---|---|
| Defining feature | Acute demyelinating CNS lesions larger than 2 cm that mimic tumors on MRI, typically with little or no mass effect relative to lesion size[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) |
| Origin of the term | "Tumefactive demyelination" coined in 1979 by van der Velden et al., from a CT scan with biopsy consistent with multiple sclerosis[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10502639/) |
| Frequency | Estimated prevalence of 1 to 3 per 1,000 cases of MS; annual incidence about 0.3 per 100,000 people[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC13285462/) |
| Who is affected | Peak onset between the second and fourth decades of life, with female predominance[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) |
| Course | 30% to 70% of patients with a tumefactive lesion develop MS over time; time to second relapse after a tumefactive lesion averages 4.8 years[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) |
| Key imaging sign | Open-ring (incomplete) enhancement has a specificity of 98% to 100% for demyelination, though sensitivity varies from 27% to 71%[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) |
| First-line treatment | High-dose intravenous methylprednisolone, 1 g per day for 3 to 5 days; plasma exchange for steroid-refractory cases[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) |
## Definition and nomenclature
There is no official definition of tumefactive demyelinating lesions, and the 2017 [McDonald criteria](https://www.edgepedia.org/mcdonald-criteria) for multiple sclerosis do not mention them.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) The literature consistently describes TDLs as acute, large (greater than 2 cm) demyelinating central nervous system lesions accompanied by cystic changes or ring enhancement on MRI, with little or no mass effect; one review proposed extending the definition to lesions between 0.5 cm and 2 cm whose MRI characteristics are likely to be mistaken for tumors.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) Chinese guidelines published for the diagnosis and management of TDLs require, absent histopathological confirmation, symptoms lasting longer than 24 hours with progression, at least one brain lesion of 2 cm or more in one direction on MRI at 1.5 T or higher, predominantly white matter involvement, a hypodense or isodense lesion, and findings not explainable by any other CNS lesion or syndrome.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/)
The term "tumefactive demyelination" was first used in 1979 by van der Velden et al. after a head CT showed a lesion whose biopsy was consistent with multiple sclerosis.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10502639/) Related names in the literature include pseudotumoral demyelinating lesions, tumor-like MS, and demyelinating pseudotumor.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10502639/) • [2](https://link.springer.com/article/10.1186/s12883-025-04495-9) The name "tumefactive MS" is slightly misleading, because a tumefactive lesion can occur as a clinically isolated syndrome or in association with other conditions such as neuromyelitis optica spectrum disorder (NMOSD), Balo's concentric sclerosis, or [acute disseminated encephalomyelitis](https://www.edgepedia.org/acute-disseminated-encephalomyelitis) (ADEM).[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) TDLs are also seen in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and aquaporin-4-IgG seropositive NMOSD.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10502639/)
## Epidemiology and course
Reviews report TDL in 1 to 3 per 1,000 cases of MS, and a systematic review of biopsy-proven lesions gives an annual incidence of 0.3 per 100,000, with demographics similar to those of MS.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) • [4](https://pmc.ncbi.nlm.nih.gov/articles/PMC13285462/) Reported age at onset ranges from 10 to 66 years, with one study reporting a mean of 27 years, and a female predominance has been described.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) A retrospective cohort of 257 patients seen at [Mayo Clinic](https://www.edgepedia.org/mayo-clinic) between 1990 and 2021 examined the natural history of the condition.[3](https://pmc.ncbi.nlm.nih.gov/articles/PMC10502639/)
**Disease course.** In 46% of patients with a TDL there is a known history of MS, but a tumefactive lesion can also be the first neurologic event; 30% to 70% of such patients develop MS over time.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) When MS does develop, the time to a second relapse after a tumefactive lesion is longer than after a typical clinically isolated syndrome, estimated at 4.8 years.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) One multicenter retrospective study from Europe and North America found that 25% of patients initially diagnosed with TMS developed relapsing-remitting MS within five years, while others had monophasic courses.[2](https://link.springer.com/article/10.1186/s12883-025-04495-9)
## Diagnosis and differentiation from tumors
The central clinical problem is distinguishing a demyelinating lesion from a glioma, primary central nervous system lymphoma, or abscess. Conventional MRI for this differentiation has a reported sensitivity of 89% and specificity of 94%.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) Several features favor demyelination, though none is pathognomonic: open-ring or incomplete rim enhancement, sparing of cortical gray matter, absent or mild mass effect and perilesional edema relative to lesion size, and a peripheral T2-hypointense rim.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) • [6](https://discovery.ucl.ac.uk/id/eprint/10174655/2/Solomon_Differential%20diagnosis%20of%20suspected%20multiple%20sclerosis-%20an%20updated%20consensus%20approach_AAM.pdf) • [2](https://link.springer.com/article/10.1186/s12883-025-04495-9) Open-ring enhancement points toward the gray matter and is present in approximately 35% to 70% of cases.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) Closed-ring enhancement, more typical of high-grade neoplasms, still occurs in about 18% of demyelinating lesions.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/)
**Advanced imaging.** On diffusion-weighted imaging, TDLs classically show high [apparent diffusion coefficient](https://www.edgepedia.org/apparent-diffusion-coefficient) in the lesion center from vasogenic edema and myelin destruction, with low ADC peripherally where inflammatory cells infiltrate.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) Dynamic susceptibility contrast perfusion measures relative cerebral blood volume, which is significantly lower in TDLs than in high-grade gliomas, with reported mean rCBV of 2.11 ± 1.12 versus 3.77 ± 1.65.[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) MR spectroscopy shows increased choline and reduced N-acetylaspartate, but this pattern overlaps with non-necrotic high-grade tumors, limiting its specificity.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) Hypoattenuated areas on CT corresponding to enhancing areas on MRI occur in 93% of tumefactive demyelinations versus 4% of tumors, and combining CT with MRI yields a sensitivity of 87% and specificity of 100% in one analysis.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/)
**Cerebrospinal fluid and biopsy.** CSF findings are frequently inconclusive: oligoclonal bands are present in 33% of TDL patients and an elevated [IgG index](https://www.edgepedia.org/igg-index) in 35%, less often than in typical MS.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) In one large series, approximately 30% of patients with TDLs underwent brain biopsy because of strong clinical suspicion of malignancy despite imaging suggestive of demyelination.[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) Biopsy is the gold standard when clinical and radiologic findings remain ambiguous.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) [Histopathology](https://www.edgepedia.org/histopathology) shows dense macrophage infiltration with myelin debris, relative preservation of axons, reactive astrocytes, and perivascular lymphocytes; stains for myelin, axons, and macrophages help separate demyelination from lymphoma or glial neoplasm.[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) • [5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/)
## Pathogenesis
TDL and MS appear to share etiologic elements: the lesions often occur concurrently with MS, show demyelination with possible perivascular edema, can exhibit oligoclonal bands in CSF, and respond to plasma exchange and rituximab.[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/) Biopsy tissue shows confluent demyelination with prominent macrophage infiltration and perivascular lymphocytic cuffs, and type II immunopattern (antibody and complement-mediated demyelination) is commonly reported.[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) B-cell presence in the lesions varies widely, from no B cells to intense infiltrates.[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC8997292/)
**Drug-associated lesions.** Some MS therapies have been linked to tumefactive demyelination, including sphingosine-1-phosphate receptor inhibitors such as fingolimod, natalizumab, and alemtuzumab.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) Published data suggest fingolimod should not be used in patients with TDL, mainly because of a possible association beyond chance between TDLs and fingolimod initiation.[8](https://www.msard-journal.com/article/S2211-0348%2817%2930072-X/fulltext)
## Treatment
Acute lesions are treated first with high-dose intravenous methylprednisolone, 1 g per day for 3 to 5 days, which reduces perilesional edema by suppressing the proinflammatory cytokine cascade.[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) Most patients improve with intravenous corticosteroids; when the response is incomplete, plasma exchange is used, and in severe cases rituximab or cyclophosphamide may be tried.[5](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/) Keegan and colleagues reported a 44% response rate to plasma exchange in patients with severe CNS demyelination.[2](https://link.springer.com/article/10.1186/s12883-025-04495-9) When a diagnosis of relapsing-remitting MS is fulfilled, conventional first-line MS disease-modifying therapy is used, with long-term choices informed by follow-up MRI, new lesion formation, and clinical relapses.[8](https://www.msard-journal.com/article/S2211-0348%2817%2930072-X/fulltext) • [2](https://link.springer.com/article/10.1186/s12883-025-04495-9)
## References
1. [Al Malik YM (2024). Tumefactive demyelinating lesions: A literature review of recent findings. Neurosciences (Riyadh) 29(3):153–160.](https://pmc.ncbi.nlm.nih.gov/articles/PMC11305340/)
2. [Jaki R, Al-Frejat Z, Bitar Z (2025). Tumefactive demyelinating lesions: a case report and literature review. BMC Neurology 25:475.](https://link.springer.com/article/10.1186/s12883-025-04495-9)
3. [Fereidan-Esfahani M, et al. (2023). Defining the natural history of tumefactive demyelination: A retrospective cohort of 257 patients. Annals of Clinical and Translational Neurology.](https://pmc.ncbi.nlm.nih.gov/articles/PMC10502639/)
4. [Biopsy-proven tumefactive demyelinating lesions: a systematic review and meta-analysis (2025).](https://pmc.ncbi.nlm.nih.gov/articles/PMC13285462/)
5. [Perez Giraldo GS, et al. (2023). Differential Diagnosis of Tumor-like Brain Lesions. Neurology Clinical Practice 13(5).](https://pmc.ncbi.nlm.nih.gov/articles/PMC10468256/)
6. [Solomon AJ, et al. Differential diagnosis of suspected multiple sclerosis: an updated consensus approach.](https://discovery.ucl.ac.uk/id/eprint/10174655/2/Solomon_Differential%20diagnosis%20of%20suspected%20multiple%20sclerosis-%20an%20updated%20consensus%20approach_AAM.pdf)
7. [Immunopathology of Tumefactive Demyelinating Lesions – From Idiopathic to Drug-Related Cases (2022). Frontiers in Neurology.](https://pmc.ncbi.nlm.nih.gov/articles/PMC8997292/)
8. [Algahtani H, Shirah B, Alassiri A (2017). Tumefactive demyelinating lesions: A comprehensive review. Multiple Sclerosis and Related Disorders 14:72–79.](https://www.msard-journal.com/article/S2211-0348%2817%2930072-X/fulltext)
---
*Topic: Encyclopedia › Life and health › Human health and medicine › Human structure and function › Nervous and sensory systems › Neurological disorders and neural injury › Brain tumors and intracranial mass lesions › Diagnosis of brain tumors*
*Initially written Sep 17, 2026 · Reviewed: Sep 17, 2026; Sep 30, 2026; Oct 21, 2026 · Edited: Sep 30, 2026; Oct 15, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license